You just read:

Cirius Therapeutics' Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting

News provided by

Cirius Therapeutics

Oct 21, 2019, 16:05 ET